agenT-797 in Participants With Relapsed/Refractory Multiple Myeloma

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

March 29, 2021

Primary Completion Date

January 13, 2023

Study Completion Date

May 31, 2023

Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
DRUG

agenT-797

agenT-797 is an off-the-shelf cell therapy consisting of ≥ 95% allogeneic human unmodified iNKT cells isolated from 1 healthy donor mononuclear cell apheresis unit and expanded ex vivo.

Trial Locations (3)

40207

Norton Cancer Institute - St. Matthews - Medical Oncology/Hematology Candida, Louisville

45267

University of Cincinnati Cancer Center, Cincinnati

02215

Dana-Farber Cancer Institute, Boston

Sponsors

Lead Sponsor

All Listed Sponsors
lead

MiNK Therapeutics

INDUSTRY

NCT04754100 - agenT-797 in Participants With Relapsed/Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter